Evidence map›Paper›PMID 40658599›Full record

ArticleCancer research2025

A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression.

Yan Zhao, Tina Andoh, Fatima Charles, Priyanka Reddy, Kristina Paul, Harsh Goar, Ishrat Durdana, Caiden J Golder, Ashley N Hardy, Marisa M Juntilla and 17 more

Abstract read
In one paragraph

Article in Cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors.

Yan ZhaoDepartments of Internal Medicine and Molecular Biology, Cecil H. and Ida Green Center for Reproductive Sciences, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0003-3003-2890
Tina AndohDepartments of Internal Medicine and Molecular Biology, Cecil H. and Ida Green Center for Reproductive Sciences, UT Southwestern Medical Center, Dallas, Texas.ORCID 0009-0004-9653-9736
Fatima CharlesDepartments of Internal Medicine and Molecular Biology, Cecil H. and Ida Green Center for Reproductive Sciences, UT Southwestern Medical Center, Dallas, Texas.ORCID 0009-0000-2842-6503
Priyanka ReddyDepartments of Internal Medicine and Molecular Biology, Cecil H. and Ida Green Center for Reproductive Sciences, UT Southwestern Medical Center, Dallas, Texas.ORCID 0009-0006-4002-6020
Kristina PaulDepartment of Genetics, Stanford University, Palo Alto, California.ORCID 0000-0003-0767-4617
Harsh GoarDepartments of Internal Medicine and Molecular Biology, Cecil H. and Ida Green Center for Reproductive Sciences, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-0759-613X
Ishrat DurdanaDepartments of Internal Medicine and Molecular Biology, Cecil H. and Ida Green Center for Reproductive Sciences, UT Southwestern Medical Center, Dallas, Texas.ORCID 0009-0003-5810-6502
Caiden J GolderDepartments of Internal Medicine and Molecular Biology, Cecil H. and Ida Green Center for Reproductive Sciences, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-0306-4793
Ashley N HardyDepartments of Internal Medicine and Molecular Biology, Cecil H. and Ida Green Center for Reproductive Sciences, UT Southwestern Medical Center, Dallas, Texas.ORCID 0009-0005-3823-4501
Marisa M JuntillaDepartment of Pathology, Stanford University, Palo Alto, California.ORCID 0000-0003-0872-9341
Soo-Ryum YangDepartment of Pathology, Stanford University, Palo Alto, California.ORCID 0000-0002-1051-502X
Chien-Yu LinDepartment of Pathology, Stanford University, Palo Alto, California.ORCID 0000-0002-4269-3234
Idit Sagiv-BarfiDepartment of Medicine, Stanford University, Palo Alto, California.ORCID 0000-0002-8372-9096
Benjamin S GellerDepartment of Genetics, Stanford University, Palo Alto, California.ORCID 0000-0003-3497-6186
Stephen MooreDepartments of Internal Medicine and Molecular Biology, Cecil H. and Ida Green Center for Reproductive Sciences, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0003-4156-5350
Dipti ThakkarHummingbird Bioscience, Singapore, Singapore.ORCID 0009-0004-9947-3779
Jerome D Boyd-KirkupHummingbird Bioscience, Houston, Texas.ORCID 0000-0002-6033-2619
Yan PengDepartment of Pathology, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0001-5765-6260
James M FordDepartment of Medicine, Stanford University, Palo Alto, California.ORCID 0000-0002-2513-7025
Melinda L TelliDepartment of Medicine, Stanford University, Palo Alto, California.ORCID 0000-0001-7993-1235
Song ZhangPeter O'Donnell Jr. School of Public Health, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-9364-4053
Allison W KurianDepartment of Medicine, Stanford University, Palo Alto, California.ORCID 0000-0002-6175-9470
Robert B WestDepartment of Pathology, Stanford University, Palo Alto, California.ORCID 0000-0002-8330-8283
Tao YueDepartments of Surgery and Immunology, Center for Organogenesis Research and Trauma, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0001-5417-2826
Andrew M LipchikEugene Applebaum College of Pharmacy and Health Science, Wayne State University, Detroit, Michigan.ORCID 0000-0003-4702-4504
Michael P SnyderDepartment of Genetics, Stanford University, Palo Alto, California.ORCID 0000-0003-0784-7987
Joshua J GruberDepartments of Internal Medicine and Molecular Biology, Cecil H. and Ida Green Center for Reproductive Sciences, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-8642-6074

Funding

UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Sandi Leigh Pruitt · 2010 to 2026
$53.7M
PreCancer Atlas of Familial Adenomatous PolyposisU2CCA233311 · NCI · STANFORD UNIVERSITY · PI SNYDER, MICHAEL P. · 2018 to 2023
$11.6M
Molecular mechanisms and therapeutic principles of VISTA+ triple-negative breast cancersR01CA290297 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI JOSHUA JAMES GRUBER · 2024 to 2026
$1.4M
Breast Cancer Research Foundation (BCRF) YIACancer Prevention and Research Institute of Texas (CPRIT) RR200090Conquer Cancer Foundation (CCF) YIAJane Coffin Childs Memorial Fund for Medical Research (JCC) FellowshipNational Cancer Institute (NCI) R01CA290297National Cancer Institute (NCI) U2CCA233311NCI NIH HHS P30 CA142543NCI NIH HHS R01 CA290297NCI NIH HHS U2C CA233311Stanford Cancer Institute WCC Innovation AwardSusan G. Komen (SGK) PDF17483383V Foundation for Cancer Research (VFCR) V2022-022
6 · The paper itself

Abstract

V-domain immunoglobulin suppressor of T-cell activation (VISTA, VSIR) is a key immune checkpoint receptor under investigation as a target for cancer immunotherapy. However, a better understanding of the signaling mechanisms of VISTA is needed to optimize the therapeutic potential. In this study, we identified a conserved four amino acid (NPGF) intracellular motif in VISTA that suppresses cell proliferation by constraining cell-intrinsic growth receptor signaling. A class of triple-negative breast cancers (TNBC) with high VISTA expression and low proliferative index was identified and characterized. The NPGF motif bound to the adapter protein NUMB and recruited Rab11 endosomal recycling machinery. The NPGF motif sequestered NUMB at endosomes, which interfered with EGFR trafficking and signaling to suppress tumor growth. These tumor-suppressive effects did not require canonical VISTA ligands or a functioning immune system. Mutation of the VISTA NPGF domain reverted VISTA-induced growth suppression in multiple breast cancer mouse models. The NPGF motif was also required for response of VISTA+ TNBCs to VISTA-blocking antibodies. These results define a mechanism by which VISTA recruits adapter proteins to control malignant epithelial cell growth and signaling. They also define distinct intracellular residues that are critical for response to therapeutic antibodies that could be exploited to improve immunotherapy. SIGNIFICANCE: Characterization of the molecular mechanisms of VISTA and elucidation of therapeutic vulnerabilities in a class of triple-negative breast cancer that strongly expresses VISTA in tumor cells could inform future immune-targeting anticancer therapies. See related commentary by Tao and Vasan, p. 3371.

Indexed as

B7 AntigensTriple Negative Breast NeoplasmsAmino Acid MotifsAnimalsCell Line, TumorCell ProliferationErbB ReceptorsFemaleHumansMembrane ProteinsMiceSignal TransductionXenograft Model Antitumor AssaysB7 AntigensErbB ReceptorsMembrane ProteinsVSIR protein, human

Identifiers

PMID40658599
PMCPMC12317733

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.